Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification

(2012) A S Betof et al.   BRITISH JOURNAL OF CANCER

Antimetastatic Effect of Sulfamate Carbonic Anhydrase IX Inhibitors in Breast Carcinoma Xenografts

(2012) Roben G. Gieling et al.   JOURNAL OF MEDICINAL CHEMISTRY

CD133 Is a Useful Surrogate Marker for Predicting Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer

(2012) Naoki Aomatsu et al.   PLoS One

Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response

(2011) Carla S. Fisher et al.   ANNALS OF SURGICAL ONCOLOGY

Interfering with pH regulation in tumours as a therapeutic strategy

(2011) Dario Neri et al.   NATURE REVIEWS DRUG DISCOVERY

New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation

(2010) P Swietach et al.   ONCOGENE

Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1α, GLUT1, and CAIX

(2010) Chi-Long Chen et al.   VIRCHOWS ARCHIV

The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy

(2009) E Y Tan et al.   BRITISH JOURNAL OF CANCER

Immunohistochemical Detection of Changes in Tumor Hypoxia

(2009) James Russell et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis

(2009) Reiki Nishimura et al.   Breast Cancer

Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome

(2008) Tadahiko Shien et al.   BREAST CANCER RESEARCH AND TREATMENT